Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor, Adult|Triple Negative Breast Cancer|Colorectal Cancer|Hepatocellular Carcinoma|Osteosarcoma|Epithelial Ovarian Cancer|Gastric Cancer|Non-small Cell Lung Cancer|Malignant Melanoma
Interventions: BIOLOGICAL: CRX100 suspension for infusion|COMBINATION_PRODUCT: Fludarabine|COMBINATION_PRODUCT: Cyclophosphamide
Sponsor: BioEclipse Therapeutics